WilburJPanMDPhD

PubMed

• 190 citations
  Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
  Javier Cortes, Hope S Rugo, David W Cescon, Seock-Ah Im, Mastura M Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Jose Perez-Garcia, Hiroji Iwata, Norikazu Ma...> ;The New England Journal of Medicine. 2022 Jul 21
• 2 citations
  Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-ana...
  Javier Cortes, Amin Haiderali, Min Huang, Wilbur Pan, Peter Schmid, Katherine G Akers, Julie E Park, Andrew M Frederickson, Peter A Fasching, Joyce O'Shaughnessy> ;BMC Cancer. 2023 Aug 23
• Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
  Min Huang, Peter A Fasching, Amin Haiderali, Weiguang Xue, Wilbur Pan, Vassiliki Karantza, Fan Yang, James Truscott, Yiqiao Xin, Joyce O'Shaughnessy> ;Future Oncology. 2024 Feb 1
• 4 citations
  Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
  Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko...> ;Cancer Medicine. 2023 May 1
• 3 citations
  Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Canc...
  Min Huang, Peter A Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicola...> ;Advances in Therapy. 2023 Mar 1
• 2 citations
  Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
  Min Huang, Joyce O'Shaughnessy, Amin Haiderali, Wilbur Pan, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Peter A Fasching> ;European Journal of Cancer. 2022 Dec 1
• 4 citations
  Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.
  Min Huang, Peter Fasching, Amin Haiderali, Wilbur Pan, Emma Gray, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O'...> ;Immunotherapy. 2022 Sep 1
• 9 citations
  Impact of Required Versus Self-Directed Use of Virtual Patient Cases on Clerkship Performance: A Mixed-Methods Study.
  Sarang Kim, Laura Rees Willett, Wilbur J. Pan, Joyce Afran, John A. Walker, Judy A. Shea> ;Academic Medicine. 2017 Oct 1
• 9 citations
  Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization
  Andrew Kopecky, Atif J. Khan, Wilbur Pan, Richard A. Drachtman, Rahul R. Parikh> ;Advances in Radiation Oncology. 2017 Jul 19
• 2 citations
  Underutilization of proton therapy in the treatment of pediatric central nervous system tumors: an analysis of the National Cancer Database
  Atif J. Khan, Benjamin H. Kann, Wilbur Pan, Richard A. Drachtman, Kenneth B. Roberts, Rahul R. Parikh> ;Acta Oncologica. 2017 Feb 13
• 8 citations
  A Stroke Mimic: Methotrexate-induced Neurotoxicity in the Emergency Department.
  Patrick J. Rogers, Wilbur Pan, Richard A. Drachtman, Christopher D. Haines> ;The Journal of Emergency Medicine. 2017 Apr 1
• 99 citations
  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
  Nathan Robison, Federico Campigotto, Susan N. Chi, Peter E. Manley, Christopher D. Turner, Mary Ann Zimmerman, Christine Chordas, Annette M. Werger, Jeffrey C. Allen, ...> ;Pediatric Blood & Cancer. 2014 Apr 1
• Join now to see all

Journal Articles

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer  
  Javier Cortes, M.D., Ph.D., Hope S. Rugo, M.D., David W. Cescon, M.D., Ph.D., Seock-Ah Im, M.D., Ph.D., Mastura M. Yusof, M.D., Carlos Gallardo, M.D., Oleg Lipatov, M...., New England Journal of Medicine, 7/21/2022
• Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer  
  Min Huang, Peter Fasching, Amin Haiderali , Wilbur Pan, Emma Gray, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen & Joyce ..., Immunotherapy, 7/7/2022